| 1. |
Science supports potential of aspirin in diabetic retinopathy |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1413,
2003,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 2. |
A tissue implant using Biopump technology delivering epoetin alfa is being assessed |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1413,
2003,
Page 3-3
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 3. |
Antibacterials + diagnostic strategy worth it in pneumonia |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1413,
2003,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 4. |
Less toxicity with pemetrexed spells savings in NSCLC |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1413,
2003,
Page 5-6
L Hunt,
Preview
|
|
摘要:
Currently, docetaxel is the standard second-line treatment for patients with non-small-cell lung cancer (NSCLC) with a good performance status, based on phase III randomised studies showing improved outcomes compared with ifosfamide, vinorelbine or best supportive care. However, in phase II studies, pemetrexed has shown clinically-relevant activity against NSCLC as initial or second-line therapy. New data presented at the 12th European Cancer Conference (ECCO) [Copenhagen, Denmark; September 2003] suggests that not only is pemetrexed similar to docetaxel in terms of clinical efficacy, it also costs less and results in fewer drug-related adverse events.1,2
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 5. |
Letrozole warranted for postmenopausal breast cancer |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1413,
2003,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 6. |
Trabectedin*shows long-term efficacy in patients with progressive or pretreated STS |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1413,
2003,
Page 7-7
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 7. |
Recently released study data support the dosing of an oral insulin tablet*just before mealtime. |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1413,
2003,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 8. |
ETC 216: regression of atherosclerosis in patients with ACS |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1413,
2003,
Page 9-9
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 9. |
Intra-articular infliximab was effective for recalcitrant knee synovitis in a patient with Behçet's disease, |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1413,
2003,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 10. |
Amoxicillin/clavulanate: new formulation effective against PRSP |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1413,
2003,
Page 11-12
P Hunter,
Preview
|
|
摘要:
A new pharmacokinetically-enhanced formulation of amoxicillin/clavulanate was effective in treating community acquired pneumonia (CAP) and acute bacterial sinusitis caused by penicillin-resistantStreptococcus pneumoniae(PRSP), according to data from seven clinical studies presented at the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) [Chicago, US; September 2003]. The analysis included four randomised comparative studies involving patients with CAP and three noncomparative studies involving patients with CAP and sinusitis. The comparator groups in these studies received other amoxicillin/clavulanate formulations. The new formulation was highly effective, even when the infecting strain was shown to be resistant to amoxicillin. The safety and tolerability of pharmacokinetically-enhanced amoxicillin/clavulanate did not differ from that of conventional formulations.
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
首页
